Camurus’ Nomination Committee appointed for the Annual General Meeting 2023

Report this content

Lund — 19 October 2022 — Camurus today announced that the Nomination Committee for the Annual General Meeting, AGM, 2023 consists of the following persons, who together represent about 50.5 percent of the total number of shares and votes in Camurus based on the last known shareholder information:

  • Per Sandberg, appointed by Sandberg Development AB,
  • Arne Lööw, appointed by Fjärde AP-fonden,
  • Henrik Didner, appointed by Didner & Gerge Fonder AB, and
  • Per Olof Wallström, Chairman of the Board

The Nomination Committee’s proposals will be presented in the Notice to the AGM 2023 and on Camurus’ website,

Shareholders who wish to submit proposals to the Nomination Committee are welcome to contact the Nomination Committee at the company’s address, Ideon Science Park, SE-223 70, Lund, Sweden. Proposals shall be submitted in due time before the Annual General Meeting, but not later than 8 February 2023, to ensure that the proposals can be adequately considered by the Nomination Committee.

The AGM 2023 in Camurus will be held at 5:00 pm CET on 10 May 2023 in Lund. Shareholders who want to have a matter addressed at the AGM 2023 must submit such a proposal to the same address as above (subject “Annual General Meeting 2023”) by 22 March 2023 at the latest.

About Camurus
Camurus is a Swedish research-based pharmaceutical company committed to developing and commercializing innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the proprietary FluidCrystal® drug delivery technologies and an extensive R&D expertise. Camurus’ clinical pipeline includes products for treatment of cancer, endocrine diseases, pain and addiction, developed in-house and in collaboration with international pharmaceutical companies. The company’s shares are listed on Nasdaq Stockholm under the ticker “CAMX”. For more information, visit

For more information
Per Olof Wallström, Chairman of the Board
Tel. +46 709 42 95 20

The information was submitted for publication at 07:00 am CET on 19 October 2022.


Documents & Links